Compare ClearPoint Neuro Inc (CLPT) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Equinor ASA — how do they compare? ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M), while Equinor ASA trades at $36.18 (market cap $83.20B). The key difference: Equinor ASA is far larger — about 173.8× ClearPoint Neuro Inc's market cap, and Equinor ASA pays a 4.2% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | EQNR | |
|---|---|---|
Market Cap | $478.63M | $83.20B |
Sector | Health | Energy |
52-Week High | $29.60 | $42.40 |
52-Week Low | $8.66 | $22.41 |
Enterprise Value | $506.63M | $94.96B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Equinor (EQNR) trades at $36.06, up 6.31% with a bullish technical outlook despite mixed earnings. The stock shows strong profitability with 37.45% gross margins and attractive valuation metrics including a P/E of 16.32 and EV/EBITDA of 2.37. Recent strategic moves include expanding Norwegian Continental Shelf operations through $410M Troll field investment and acquiring BP's Bay du Nord stake, positioning for production growth.
EQNR presents a balanced opportunity with solid fundamentals and strategic growth initiatives, though declining revenue and net income trends warrant monitoring. Analyst sentiment is mixed with 30% buy ratings, while technical indicators suggest near-term strength. Key risks include volatile energy prices and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
